Targeted radio-nuclide therapy of skeletal metastases

Cancer Treatment Reviews

Volumn 39, Issue 1, 2013, Pages 18-26

  Sartor, Oliver ^a   Hoskin, Peter ^b,c   Bruland, Øyvind S ^d,e  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alpha particle; Bone; Prostate cancer; Radiopharmaceuticals; Radium 223; Samarium 153; Stroma; Strontium 89; Targeted therapy

Indexed keywords

BONE SEEKING RADIOPHARMACEUTICAL; BORTEZOMIB; HOLMIUM; HOLMIUM 166; IODINE 131; LEXIDRONAM SAMARIUM SM 153; LUTETIUM 177; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; RADIUM; RADIUM 223; RHENIUM 186; RHENIUM 188; STRONTIUM 89; TIN; TIN 117M; UNCLASSIFIED DRUG; YTTRIUM 90;

BONE METASTASIS; CANCER RADIOTHERAPY; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; REVIEW;

BONE NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84869081194     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.03.006     Document Type: Review

References (62)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
2. Paget S. The distribution of secondary growth in cancer of the breast. Lancet 1889, 1:571-573.
3. Chung L.W. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 2003, 97:772-778.
4. Casimiro S., Guise T.A., Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009, 310:71-81.
5. Nagrath S., Sequist L.V., Maheswaran S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
6. Berg A., BrulandØ S., Fosså S.D., et al. Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer. Prostate 2008, 68:1607-1614.
7. Cooper C.R., Chay C.H., Gendernalik J.D., et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003, 97:739-747.
8. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11:411-425.
9. Gleave M.E., Hsieh J.T., von Eschenbach A.C., Chung L.W. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 1992, 147:1151-1159.
10. Dougall W.C., Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006 Dec, 25(4):541-549.
11. Loberg R.D., Logothetis C.J., Keller E.T., Pienta K.J. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005, 23:8232-8241.
12. Lee S.E., Min C.K., Yahng S.A., et al. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma. Eur J Haematol 2011, 86:83-86.
13. Shah S.K., Ryan C.J., Kilian C., et al. Bone scan "flare" in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. J Clin Oncol 2010, 28:15s.
14. Vogel C.L., Schoenfelder J., Shemano I., Hayes D.F., Gams R.A. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995, 13:1118-1123.
15. Pandit-Taskar N., Batraki M., Divgi C.R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004, 45:1358-1365.
16. 223Ra: adjuvant or alternative to conventional modalities?. Clin Cancer Res 2006, 12:6250s-6257s.
17. Sgouros G., Roeske J.C., McDevitt M.R., et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010, 51:311-328.
18. Anderson R.M., Stevens D.L., Sumption N.D., et al. Effect of linear energy transfer (LET) on the complexity of alpha-particle induced chromosome aberrations in human CD341 cells. Radiat Res 2007, 167:541-550.
19. Tamada T., Sone T., Tomomitsu T., Jo Y., Tanaka H., Fukunaga M. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 2001, 19:45-51.
20. Brown J.E., Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia 2010, 12:685-696.
21. Jung K., Lein M., Stephan C., Von Hösslin K., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004, 111:783-791.
22. Nilsson S., Balteskard L., Fosså S.D., et al. First clinical experiences with alpha emitter radium-223 in the treatment of skeletal metastases from breast and prostate cancer. Clin Cancer Res 2005, 11:4451-4459.
23. Nilsson S., Franzén L., Parker C., et al. Bone-targeted radium-223 in symptomatic, hormone refractory prostate cancer: a randomized, placebo-controlled, phase 2 study. Lancet Oncol 2007, 8:587-594.
24. Fan Y., Luo R., Li G., Huang K. Evaluation of therapeutic effects of strontium-89 on osseous metastases of prostate cancer by bone scanning and B-ALP measurement. Zhonghua Nan Ke Xue 2004, 10:178-181.
25. de Klerk J.M., van het Schip A.D., Zonnenberg B.A. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 1996, 37:244-249.
26. Papatheofanis F.J. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma. J Nucl Med 1997, 38:1175-1179.
27. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011, 32:168-176.
28. Windsor P.M. Predictors of response to strontium-89 (Metastron®) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Clin Oncol 2001, 13:219-227.
29. Silberstein E.B. Dosage and response in radiopharmaceutical therapy of painful osseous metastases. J Nucl Med 1996, 37:249-252.
30. Lewington V.J., McEwan A.J., Ackery D.M., et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991, 27:954-958.
31. Buchali K., Correns H.J., Schuerer M., et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988, 14:349-351.
32. Porter A.T., McEwan A.J.B., Powe J.E., et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external-beam irradiation in the management of endocrine-resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993, 25:805-813.
33. Porter AT, Crispen RG, Sadasiban R et al. Tumoricidal effect of strontium-89 in prostate cancer based on PSA and pain delay. ASCO 1997 Annual Meeting, Abstract 1214.
34. Smeland S., Erikstein B., Aas M., Skovlund E., Hess S.L., Fosså S.D. Role of strontium-89 as a adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 2003, 56:1397-1404.
35. Oosterhof G.O., Roberts J.T., de Reijke T.M., et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation of Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003, 44:519-526.
36. Quilty P.M., Kirk D., Bolger J.J., et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994, 31:33-40.
37. 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997, 33:1583-1591.
38. Serafini A.N., Houston S.J., Resche I., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 EDTMP: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998, 16:1574-1581.
39. Sartor O., Reid R.H., Hoskin P.J., et al. Samarium-153-EDTMP complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004, 63:940-945.
40. Maxon H.R., Schroder L.E., Thomas S.R., et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990, 176:155-159.
41. de Klerk J.M., Zonnenberg B.A., van het Schip A.D., et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994 Oct, 21(10):1114-1120.
42. Han S.H., de Klerk J.M., Tan S., et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002, 43:1150-1156.
43. Palmedo H., Manka-Waluch A., Albers P., et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003, 21:2869-2875.
44. [accessed 15.07.11]. http://clinicaltrials.gov/ct2/show/NCT00699751.
45. Parker C., Heinrich D., O'Sullivan J.M., et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 2011, 47(Suppl. 2):3.
46. 153Sm EDTMP to patients with metastatic bone pain. Cancer 2007, 109:637-643.
47. Tu S.M., Millikan R.E., Mengistu B., et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized Phase II trial. Lancet 2001, 357:336-341. Erratum in: Lancet 2001; 357:1210.
48. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002, 43:79-86.
49. Morris M.J., Pandit-Taskar N., Carrasquillo J., et al. Phase I study of samarium-153 EDTMP with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 2009, 27:2436-2442.
50. Fizazi K., Beuzeboc P., Lumbroso J., et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009, 27:2429-2435.
51. 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). Eur J Nucl Med Mol Imaging 2011, 38:1990-1998.
52. [accessed 15.07.11]. http://www.mskcc.org/mskcc/html/2270.cfm?IRBNO=10-086.
53. 153Sm-EDTMP: a new promising approach. Acta Oncol 1996, 35:381-384.
54. Anderson P.M., Wiseman G.A., Dispenzeri A., et al. High dose 153-samarium ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002, 20:189-196.
55. Anderson P.M., Wiseman G.A., Erlandson L., et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005, 11:6895-6900.
56. Storto G., Klain M., Paone G., et al. Combined therapy Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006, 39:35-41.
57. 188Re-HEDP and pamidronate in breast cancer with bone metastasis. Zhonghua Zhong Liu Za Zhi 2005, 27:180-182.
58. 186Re-HEDP treatment in cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 2008, 35:1392-1393.
59. 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 2008, 35:756-765.
60. Goel A., Dispenzieri A., Geyer S.M., et al. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Eur J Nucl Med Mol Imaging 2011, 38:1990-1998.
61. Iuliano F, Molica S, Abruzzese E, Peta A, Toraldo A, Palermo S. Samarium-153Sm-EDTMP and zoledronic acid present synergistic action and are able to control pain and significantly improve QoL in elderly patients with MM. (Results of a phase II trial and 19months follow up). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). vol. 22, No 14S (July 15 Supplement), 2004: 6737.
62. Berenson J.R., Yellin O., Patel R., et al. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2009, 15:1069-1075.